Dulaglutide (Trulicity)
Dulaglutide (LY2189265), a recombinant GLP-1 receptor agonist fused to a modified human IgG4 Fc fragment (PMID 25912221; FDA label 2025).
Approved status applies to specific products, routes, and indications, not every use context discussed online.
An FDA-approved once-weekly injection (Trulicity) for type 2 diabetes that controls blood sugar and also reduces the risk of heart attack and stroke in people with heart disease or multiple risk factors. Also approved for children age 10 and older with type 2 diabetes.
Safety Summary
In a pooled analysis of 787 Chinese patients from AWARD-CHN1/CHN2, 28.6% reported at least one GI treatment-emergent adverse event (TEAE) by week 26. The most frequent were diarrhea (13.1%), nausea (6.6%), abdominal distension (6.4%), and vomiting (3.0%). Per FDA label, GI events were graded mild in approximately 48-58%, moderate in 35-42%, and severe in 7-11% of cases, with events peaking during the first 2 weeks and declining thereafter (PMID 32621083; FDA label 2025). Pancreatic amylase increased modestly within normal range (LS mean +5.7 U/L at 26 weeks) without associated pancreatitis events (PMID 34453682).
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-21]